Transcription profiling of human tumours at baseline and after 21 days of treatment with sorafenib and dacarbazine

ABSTRACT: Background New approaches are needed to improve prognostic accuracy for treatment response and to explore the complexities of drug effects on human tumours. We developed a strategy of global genomic investigation of sequential tumor biopsies at baseline and 21 days post-treatment, and applied this approach in a phase I study of sorafenib plus dacarbazine in patients with solid tumours. Methods 23 patients received 21-day cycles of oral sorafenib, 400 mg twice daily and dacarbazine, 1000 mg/m2 by 1-h intravenous infusion on day 1. Efficacy was assessed using response evaluation criteria in solid tumours. Differential gene expression was assessed through genomic microarray analysis of biopsy tissue from the same tumour at baseline and on day 21. Seven parameters characterizing vascularisati

ORGANISM(S): Homo sapiens

SUBMITTER: Lazar V 

PROVIDER: S-ECPF-TABM-760 | biostudies-other | 2014 Apr

REPOSITORIES: biostudies-other